Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of CHS-114 in Participants With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1 Study of CHS-114 in Participants With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CHS 114 (Primary) ; Toripalimab (Primary)
  • Indications Carcinoma; Head and neck cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man

Most Recent Events

  • 30 Apr 2025 Results (As of October 20, 2024, n=30) assessing safety and efficacy of CHS-114 with and without anti-PD-1 antibody toripalimab in patients with advanced solid tumors presented at the 116th Annual Meeting of the American Association for Cancer Research
  • 28 Apr 2025 According to a Coherus BioSciences media release, data from this study evaluating CHS-114 as monotherapy and in combination with toripalimab in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) evaluating two pharmacologically active doses of CHS-114 for dose optimization. These data are being presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois.
  • 28 Apr 2025 Results presented in the Coherus BioSciences Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top